Abstract Nanoparticle drug delivery systems are reshaping pharmaceutical development by enabling programmable control over biodistribution, cellular uptake & release kinetics beyond the limits of conventional formulations. Advances in lipid, polymeric, inorganic and hybrid nanocarriers now support delivery of small molecules, biologics, nucleic acids and gene editing cargos across oncology, cardiometabolic, infectious and neurodegenerative disease domains. Materials level engineering, spanning interfacial chemistry, supramolecular assembly and stimuli responsive matrices has enabled improved solubilization of poorly bioavailable drugs, enhanced tissue targeting and reduced systemic toxicity. Despite these therapeutic advantages, translation from laboratory systems to commercial pharmaceutical products remains constrained by manufacturing reproducibility, sterilization compatibility, endotoxin control, long term stability and regulatory uncertainty regarding nano specific safety endpoints. Industrial implementation therefore requires tight control of critical quality attributes, integration of continuous manufacturing routes and adoption of predictive modelling tools for formulation design and lifecycle risk assessment. Emerging Industry 6.0 aligned technologies including AI assisted formulation optimization, digital twin process modelling and real time process analytical technologies are beginning to transform nanomedicine from a formulation challenge into a data driven manufacturing discipline. In parallel, safe by design materials engineering and integrative nanotoxicology frameworks are improving regulatory confidence by linking physicochemical properties to biodistribution, clearance and immunological responses. These developments indicate a transition from first generation nanocarriers toward intelligent, scalable pharmaceutical systems capable of supporting precision therapeutics. The convergence of advanced materials chemistry, automated smart/ intelligent manufacturing and predictive safety science is expected to accelerate clinical translation, reduce development risk, and establish nanomedicine as a core platform across the future pharmaceutical landscape.
Majeed et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: